These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18814768)

  • 1. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
    Golay A
    Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
    Scheen AJ; Van Gaal LF
    Eur Heart J; 2007 Jun; 28(11):1401-2; author reply 1402. PubMed ID: 17493946
    [No Abstract]   [Full Text] [Related]  

  • 4. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
    Green JB; Feinglos MN
    Curr Diab Rep; 2007 Oct; 7(5):369-75. PubMed ID: 18173970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].
    Scheen AJ; Paquot N; Van Gaal LF
    Rev Med Suisse; 2008 Aug; 4(168):1812-7. PubMed ID: 18814765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].
    Roussel R
    Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():33-5. PubMed ID: 17961659
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimonabant in obese patients with type 2 diabetes.
    Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
    Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
    [No Abstract]   [Full Text] [Related]  

  • 13. Rimonabant in obese patients with type 2 diabetes.
    Shapiro H; Singer P
    Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091
    [No Abstract]   [Full Text] [Related]  

  • 14. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 15. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.
    Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994
    [No Abstract]   [Full Text] [Related]  

  • 16. Rimonabant: obituary for a wonder drug.
    Boekholdt SM; Peters RJ
    Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
    [No Abstract]   [Full Text] [Related]  

  • 17. Does rimonabant pull its weight for type 2 diabetes?
    Cleland SJ; Sattar N
    Lancet; 2006 Nov; 368(9548):1632-4. PubMed ID: 17098066
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of rimonabant on weight reduction and cardiovascular risk.
    Astrup A
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
    Seissler J
    MMW Fortschr Med; 2008 May; 150(18):27-31. PubMed ID: 18533605
    [No Abstract]   [Full Text] [Related]  

  • 20. New options for drug treatment of obesity in patients with Type 2 diabetes.
    Kennedy RL; Khoo EY
    Diabet Med; 2005 Sep; 22 Suppl 4():23-6. PubMed ID: 16109016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.